Abstract
Glycosylation, linking the glycan chains to protein or lipid, is the most common and complex post-translational modifications of proteins. One of the important functions of glycoprotein is to maintain the ordered social life of each cell in multicellular organisms. Glycosylation is sensitive to the biochemical environment leading to the alteration of glycan chains under the physiological condition and specific diseases such as cancer. Cancer and other lethal diseases cannot be diagnosed at early stage due to classic biomarker’s low sensitivity and specificity. Recently, the development of glycan profiling technologies has offered great promises for understanding the complex glycan structures and has increased interest in applying this technology for cancer studies. In this regard, to identify the glycans as the potential biomarkers of cancer has become an important direction for clinical cancer diagnosis. This paper summarizes the current research on validating and developing of the glycans as new cancer biomarkers and the nascent field of glycomics
Keywords: Cancer biomarker, glycomics, N-glycan, oligosaccharide, personalized medicine, public health pharmacogenomics.
Current Pharmacogenomics and Personalized Medicine
Title:Validation and Development of N-glycan as Biomarker in Cancer Diagnosis
Volume: 11 Issue: 1
Author(s): Wei Wang
Affiliation:
Keywords: Cancer biomarker, glycomics, N-glycan, oligosaccharide, personalized medicine, public health pharmacogenomics.
Abstract: Glycosylation, linking the glycan chains to protein or lipid, is the most common and complex post-translational modifications of proteins. One of the important functions of glycoprotein is to maintain the ordered social life of each cell in multicellular organisms. Glycosylation is sensitive to the biochemical environment leading to the alteration of glycan chains under the physiological condition and specific diseases such as cancer. Cancer and other lethal diseases cannot be diagnosed at early stage due to classic biomarker’s low sensitivity and specificity. Recently, the development of glycan profiling technologies has offered great promises for understanding the complex glycan structures and has increased interest in applying this technology for cancer studies. In this regard, to identify the glycans as the potential biomarkers of cancer has become an important direction for clinical cancer diagnosis. This paper summarizes the current research on validating and developing of the glycans as new cancer biomarkers and the nascent field of glycomics
Export Options
About this article
Cite this article as:
Wang Wei, Validation and Development of N-glycan as Biomarker in Cancer Diagnosis, Current Pharmacogenomics and Personalized Medicine 2013; 11 (1) . https://dx.doi.org/10.2174/1875692111311010008
DOI https://dx.doi.org/10.2174/1875692111311010008 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Copper Concentrations in Breast Cancer: A Systematic Review and Meta-Analysis
Current Medicinal Chemistry Development of Anti-HIV Agents Targeting Dynamic Supramolecular Mechanism: Entry and Fusion Inhibitors Based on CXCR4/CCR5 Antagonists and gp41-C34-Remodeling Peptides
Current HIV Research Recent Progress of Novel Steroid Derivatives and Their Potential Biological Properties
Mini-Reviews in Medicinal Chemistry Biological and Chemical Diversity of Coral-Derived Microorganisms
Current Medicinal Chemistry Nanoparticles in Combating Cancer: Opportunities and Limitations: A Brief Review
Current Medicinal Chemistry Vascular Mimicry: Concepts and Implications for Anti-Angiogenic Therapy
Current Angiogenesis (Discontinued) QSAR Study of Androstenedione Analogs as Aromatase Inhibitors
Letters in Drug Design & Discovery Multifunctionalized Microbubbles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Hypoxia-Inducible Factors and Sphingosine 1-Phosphate Signaling
Anti-Cancer Agents in Medicinal Chemistry Suppression of Oncoprotein Her-2 and DNA Damage after Treatment with Flavan-3- ol Vitis labrusca Extract
Anti-Cancer Agents in Medicinal Chemistry New Perspectives in the Pharmacological Potential of Naringin in Medicine
Current Medicinal Chemistry Drug Delivery Systems Based on Polymeric Micelles and Ultrasound: A Review
Current Pharmaceutical Design PET Imaging of Beta-Adrenoceptors in Human Brain: A Realistic Goal or a Mirage?
Current Pharmaceutical Design Cancer Stem Cells and the Biology of Brain Tumors
Current Stem Cell Research & Therapy The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs
Clinical Cancer Drugs Protective Role of Natural Products in Cisplatin-Induced Nephrotoxicity
Mini-Reviews in Medicinal Chemistry A Review on Important Histone Acetyltransferase (HAT) Enzymes as Targets for Cancer Therapy
Current Cancer Therapy Reviews Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
Current Cancer Drug Targets Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
Current Drug Metabolism Development of Prolactin Receptor Antagonists: Same Goal, Different Ways
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)